1st Quarter - Amendment

PARRY, ROMANI, DECONCINI & SYMMS for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 7, 2008 $40,000 Replaced
1st Quarter - Amendment Apr 15, 2008 $40,000 Replaced
1st Quarter - Amendment (this page) Jul 9, 2008 $30,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Oppose importation of unsafe drugs from outside the United States. Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1082 (110th), S. 1145 (110th)

Law Enforcement/Crime/Criminal Justice LAW

Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Financial Institutions/Investments/Securities FIN

Monitor legislation reforming the Committee on Foreign Investment in the United States process.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.